Protocol Ledger

NCT06145893 · Phase III · RECRUITING

A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

Interventional Phase III clinical trial protocol NCT06145893 sponsored by Ganzhou Hemay Pharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-13 Enrollment: 162 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06145893
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)162 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06145893
Protocol FieldVerified Registry Value
NCT IdentifierNCT06145893
Consolidated Lead SponsorGanzhou Hemay Pharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment162 participants (ESTIMATED)
Registered Start Date2023-11-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI